Dr Reddy

Dr Reddy’s Lab beats analysts’ Q2 result projections by huge margins

Dr Reddy’s Lab beats analysts’ Q2 result projections by huge margins

Indian pharmaceuticals firm Dr. Reddy’s Laboratories (DRL) on Thursday reported an impressive year-on-year increase of 76 per cent in net profit for the second quarter of current financial year, beating analysts’ average projection by a notable margins.

Hyderabad-based DRL announced that its profit after tax (PAT) jumped to Rs 690.3 crore in the July-September quarter of this year, as against Rs 392.5 crore in the corresponding quarter of last year. A group of analysts surveyed by Bloomberg had projected a net profit of around Rs 448 crore for the company’s second quarter.

Dr Reddy’s Gets Approval for Zoledronic Acid Injection

Dr Reddy’s Gets Approval for Zoledronic Acid Injection

Zoledronic acid injection has been launched by Dr Reddy's Laboratories (DRL) recently in the US market. It is after the green signal for the injection shown by the United States Food & Drug Administration (USFDA).

The company had put forth abbreviated new drug application (ANDA) for the approval of the injection. The US health regulator approved the same.

Anji Reddy Dies, Survives by Son and Daughter

Anji Reddy Dies, Survives by Son and Daughter

He helped India in establishing its reputation as inexpensive medicine supplier to the world. And he would be remembered forever for his unmatched contribution. Unfortunately, Anji Reddy, who is being talked about, died on Friday.

It has been found that the man, 72, had been suffering from a prolonged illness i. e. cancer. The pharmaceutical industry pioneer had founded as well as chaired Dr. Reddy's Laboratories Ltd. The company is the second-largest pharmaceutical company in India by market capitalization of Rs 31,000 crore.

Stock in Dr Reddy's Lab jumps after Finasteride tablets’ launch in US

Stock in Dr Reddy's Lab jumps after Finasteride tablets’ launch in US

Stock in Dr Reddy's Laboratories gained as much as 2.7 per cent to Rs 1,886.80 a share on the Bombay Stock Exchange (BSE) on Thursday, after the drug firm announced the launch of its generic Finasteride tablets in the American market.

Dr Reddy's Laboratories announced that it had launched Finasteride tablets, for treating male pattern hair loss, in the strength of 1 mg in the U. S. market on January 2 after regulators approved its abbreviated new drug application
(ANDA) with 180-day of marketing exclusivity.

Dr Reddy's Labs Launch Fondaparinux Sodium Injections

Dr Reddy's Labs Launch Fondaparinux Sodium InjectionsDr Reddy's Laboratories and Brisbane based Alchemia Ltd, finally got an approval to launch the three generic products in USA.

The US Food and Drug Administration (USFDA) sanctioned it. These Fondaparinux Sodium injections will be used for the curing deep vein thrombosis (DVT).

Dr. Reddy’s have been allotted a manufacturing license under which the injection will be entering the US markets.

Dr Reddy's consolidated net up 57 % in Q4

Dr Reddy's consolidated net up 57 % in Q4Increasing on several good product releases in the US generics market, the fourth quarter results posted by pharma Major Dr Reddy based in Hyderabad had been welcomed by the stock market. The scrip had increased by 3.29% on the BSE yesterday.

Dr. Reddy’s gas leak kills two

Dr. Reddy’s gas leak kills two

On Wednesday, Dr. Reddy, one of the major pharmacy companies of the country, witnessed a tragedy when nitrogen leaked in one of their units at Bollaram. The leak took the life of 2 innocent employees at the drug manufacturing unit when they inhaled the leaked nitrogen.

The dreaded incident took place in the production block at the ‘clean room’ where the two employees production chemist Chiranjeevi Sreedhar Reddy (38) and a contract worker Deepak Jena (22) were busy handling the process of micronisation of Omeprazole powder.

Injunction Granted To Dr Reddy’s Laboratories

Injunction Granted To Dr Reddy’s Laboratories

A preliminary injunction was charged against Indian drug maker by a U. S court for distributing Allegra-D, a generic version of an allergy drug.

Dr Reddy’s Laboratories, the drug maker states that the company disagrees with the decision made by the court. In a statement, the company said that it intends to appeal. Sanofi Aventis and Albany Molecular sought this injunction against the Indian drug maker.

Dr Reddy’s Laboratories lags expectations in quarterly profit

Dr Reddy’s

The Hyderabad based NYSE listed Pharma , Dr. Reddy’s Laboratories , reported a net profit of Rs 166.7 crore for the quarter which ended March 31 , 2010 , compared with a loss of Rs 977 crore in the year ago period , helped by the absence of any further provisioning for losses on its German Acquisition. It may be noted that the revenue feel 18 percent to 16.4 billion rupees, as sales in the United States, its biggest export market, nearly halved to 3.5 billion and European revenue declined by a third to 2.1 billion.

Dr Reddy's announces bonus debentures worth $116 million

Dr Reddy's announces bonus debentures worth $116 million

India's leading drug maker, Dr Reddy's Laboratories Ltd on Wednesday announced that it will issue bonus debentures amounting to $116 million to its shareholders.

The company will issue six bonus debentures for every one share held while the coupon rate on the offering will be decided by the board, according to statement filed by the company with the New York stock exchange.